Seite auswählen


LentiBOOST™ is a highly effective, non-cytotoxic chemical lentiviral transduction enhancer for preclinical and clinical applications. As universal acting (receptor independent) adjuvant it can be applied to a wide range of clinically relevant cell types including CD34+ hematopoietic stem cells (HSCs), primary T cells and NK cells. These unique features make it a promising candidate to improve clinical transduction protocols for ex vivo gene therapies and CAR-T cell therapies.

Read about LentiBOOST™ in the news.

Available in two grades;

LentiBOOST™ pharma grade

for use in preclinical research and process development. Available for evaluation studies under MTA. Licensing options for Research Use, Development and Commercial Use are available.
Please inquire with

LentiBOOST™ GMP grade

for use in clinical stage protocols. Currently included in Phase III and I/II clinical trials in the US and in Europe. Licensing options for Commercial Use and Development are available.
Please inquire with

In the demonstration above, LentiBOOST™ increases transduction by a factor of 5.

Benefits for Drug Development at a glance

Improved lentiviral transduction efficiency, up to 90%.
⇒ Increased expression levels of therapeutic protein have a favorable effect on success rates of clinical trials.

Positive impact on cell proliferation for CD34+ and T cells.
⇒ Reduced cost of goods, optimized and stable transgenic cell manufacturing.

Increased vector copy numbers per cell.
⇒ Strong and durable therapeutic protein expression, in line with FDA/EMA criteria for ATMPs production.

Successful track record of integration into clinical trials (III and I/II) in the US and Europe.
⇒ Proven lack of cell toxicity and prior clinical applications expedite IND filing.

GMP grade batches available.
⇒ Direct integration into clinical programs possible.

Contact us to discover how this adjuvant can excel your program: